Gilead Sciences Inc (GILD) has declared a quarterly dividend of $0.79 per share, payable to shareholders of record. The ex-dividend date is set for December 14, 2025, meaning investors must own shares before this date to qualify for the dividend. Eligible shareholders will receive their payments on December 29, 2025.
With a dividend yield of 2.66%, Gilead continues its commitment to providing regular income to its shareholders. This update provides insight into the company’s cash flow generation and capital allocation strategy.
Gilead, a biopharmaceutical company headquartered in Foster City, California, focuses on developing medicines for unmet medical needs, including HIV, viral hepatitis, COVID-19, and cancer. The firm has a market cap of $148.1 billion and a P/E ratio of 18.26. Its upcoming earnings report is scheduled for August 4, 2026, with an estimated EPS of $2.22 and revenue expectations of $7.6 billion.
Such decisions reflect Gilead's ongoing pattern of regular dividend payments, which can be attractive to income-focused investors. However, it is important for investors to review the company's dividend history and overall financial health when evaluating the sustainability of these payments.